Zevra Reports Positive Phase 2 Results for IH Drug Candidate

Zevra Therapeutics announced positive topline results from its phase 2 clinical trial evaluating KP1077 for idiopathic hypersomnia (IH).

Related Keywords

, Putilich Dreamstime , Christopher Drake , Neil Mcfarlane , Drug Administration , Zevra Therapeutics , Epworth Sleepiness Scale , Idiopathic Hypersomnia Severity Scale , Sleep Inertia Visual Analog Scale , Brain Fog ,